Nephropathology Associates
Nephropathology Associates is recorded as a service provider in 17 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 17 of 17 trials · Latest update first
A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients with Antibody Mediated Rejection.
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Sponsor Maze Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A prospective, post-authorisation long-term follow up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Sponsor Apellis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- The study enrolled 124 participants at 122 sites across 18 countries; enrollment was highest in the United States (31), Brazil (19), and Italy (17).
- Recruitment started on 30 May 2022, and the global end-of-trial date was 14 January 2025.
- A protocol amendment changed planned enrollment from 90 to 80–100 participants.
- An amendment removed eGFR from the primary efficacy endpoint and moved primary and key secondary efficacy assessments from Week 52 to Week 26.
- An amendment increased the screening period from 8 to 10 weeks and total study participation duration to 70 weeks.
- Eligibility and dosing amendments increased the minimum body weight to 30 kg and added weight-based dosing regimens for adolescents.
- The minimum planned adolescent enrollment was increased from 8 to 10 participants.
- Follow-up for participants who did not continue pegcetacoplan was shortened from 24 to 8 weeks.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients with Systemic Lupus Erythematosus with or without Active Lupus Nephritis
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation
Sponsor Alexion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An open-label, uncontrolled, multicenter study to assess the effect of zigakibart treatment on histologic, circulating, and excreted markers of kidney disease and dysfunction in adult patients with IgA nephropathy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Open‑label Trial to Evaluate the Long‑term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy.
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
Sponsor Apellis Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function (Varvara)
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
Sponsor Otsuka Pharmaceutical Development And Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER).
Sponsor Alpine Immune Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double‑blind, Placebo‑controlled, Dose‑finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Sponsor Alexion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Sponsor Alexion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC‑MPGN
Sponsor Apellis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Nephropathology Associates?
The 2026-10-09 snapshot links Nephropathology Associates to 17 distinct CTIS trials. Recorded services include Laboratory services, Kidney biopsy reading, APOL1 Genotyping, Central Biopsy Reading, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Nephropathology Associates?
The most frequently recorded therapeutic areas are Nephrology, Transplantation, Genetic and Congenital Disorders, Immunology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Nephropathology Associates conducted?
The linked trials record locations in 23 countries, including Italy, Germany, Spain, France, Czechia. These are trial locations, not confirmed office locations or countries where Nephropathology Associates delivered services.
What can this page tell me about Nephropathology Associates's trial experience?
Browse 17 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Nephropathology Associates. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Nephropathology Associates PLC